相似文献
1
Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.
Cancer Sci. 2008 Jul;99(7):1311-8. doi: 10.1111/j.1349-7006.2008.00836.x. Epub 2008 May 21.
2
Novel therapy for nasopharyngeal carcinoma--where are we.
Oral Oncol. 2014 Sep;50(9):798-801. doi: 10.1016/j.oraloncology.2014.01.002. Epub 2014 Jan 22.
3
The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma.
Br J Radiol. 2019 Oct;92(1102):20181031. doi: 10.1259/bjr.20181031. Epub 2019 May 24.
4
Advances in systemic treatment for nasopharyngeal carcinoma.
Chin Clin Oncol. 2016 Apr;5(2):21. doi: 10.21037/cco.2016.03.03.
5
Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Cancer. 2017 Jul 15;123(14):2642-2650. doi: 10.1002/cncr.30541. Epub 2017 Feb 21.
6
Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.
Expert Rev Anticancer Ther. 2006 Mar;6(3):383-94. doi: 10.1586/14737140.6.3.383.
7
Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
Ann Palliat Med. 2022 Mar;11(3):1147-1152. doi: 10.21037/apm-22-168.
8
Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic.
Am Soc Clin Oncol Educ Book. 2014:149-53. doi: 10.14694/EdBook_AM.2014.34.149.
9
Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
Anticancer Drugs. 2015 Nov;26(10):1017-25. doi: 10.1097/CAD.0000000000000276.
10
State-of-the-art management of nasopharyngeal carcinoma: current and future directions.
Br J Cancer. 2005 Mar 14;92(5):799-806. doi: 10.1038/sj.bjc.6602449.
引用本文的文献
1
EBV Vaccines in the Prevention and Treatment of Nasopharyngeal Carcinoma.
Vaccines (Basel). 2025 Apr 29;13(5):478. doi: 10.3390/vaccines13050478.
2
Effects of Arctigenin in Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma 5-8F Cells.
Anticancer Agents Med Chem. 2023;23(10):1211-1216. doi: 10.2174/1871520623666230228155129.
3
Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis.
J Cancer Res Clin Oncol. 2023 Jun;149(6):2327-2344. doi: 10.1007/s00432-022-04355-w. Epub 2022 Oct 27.
4
M1 stage subdivisions based on F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma.
Ther Adv Med Oncol. 2022 Aug 12;14:17588359221118785. doi: 10.1177/17588359221118785. eCollection 2022.
5
Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis.
Pan Afr Med J. 2022 Jan 3;41:6. doi: 10.11604/pamj.2022.41.6.28946. eCollection 2022.
6
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.
Eur Arch Otorhinolaryngol. 2022 Aug;279(8):3947-3956. doi: 10.1007/s00405-021-07192-8. Epub 2022 Jan 4.
7
Lipid-Polymer Hybrid Nanoparticle-Based Combination Treatment with Cisplatin and EGFR/HER2 Receptor-Targeting Afatinib to Enhance the Treatment of Nasopharyngeal Carcinoma.
Onco Targets Ther. 2021 Apr 9;14:2449-2461. doi: 10.2147/OTT.S286813. eCollection 2021.
8
Prognostic value of early radiological response to first-line platinum-containing chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Cancer Med. 2020 Feb;9(3):920-930. doi: 10.1002/cam4.2751. Epub 2019 Dec 13.
9
Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
BMC Cancer. 2019 Jan 21;19(1):92. doi: 10.1186/s12885-019-5281-5.
10
The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma.
Radiat Oncol. 2019 Jan 17;14(1):9. doi: 10.1186/s13014-019-1213-4.
本文引用的文献
1
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
N Engl J Med. 2007 Oct 25;357(17):1705-15. doi: 10.1056/NEJMoa070956.
2
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
Cancer Chemother Pharmacol. 2008 Jun;62(1):59-64. doi: 10.1007/s00280-007-0575-8. Epub 2007 Aug 29.
3
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
J Clin Oncol. 2007 Aug 20;25(24):3766-73. doi: 10.1200/JCO.2006.10.2871.
4
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition.
Nat Rev Cancer. 2007 Jun;7(6):475-85. doi: 10.1038/nrc2152.
5
Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging?
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):148-54. doi: 10.1016/j.ijrobp.2007.02.032. Epub 2007 May 21.
6
Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial.
Eur J Cancer. 2007 Jun;43(9):1399-406. doi: 10.1016/j.ejca.2007.03.022. Epub 2007 Apr 27.
7
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma.
Cancer Lett. 2007 Aug 8;253(1):74-88. doi: 10.1016/j.canlet.2007.01.012. Epub 2007 Feb 22.
8
Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes.
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1004-10. doi: 10.1016/j.ijrobp.2006.06.016.
9
Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
J Clin Oncol. 2006 Dec 1;24(34):5414-8. doi: 10.1200/JCO.2006.07.7982.
10
Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays.
J Gen Virol. 2006 Oct;87(Pt 10):2885-2890. doi: 10.1099/vir.0.81906-0.
Zotero 插件